Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept

References

• Tsiodras S., Samonis G., Boumpas D. T., Kontoyiannis D. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181–94
   PubMed Web of Science ®Google Scholar
• Tran T. A., DuPree M., Carlson J. A. Neutrophilic lobular (pustular) panniculitis associated with rheumatoid arthritis: a case report and review of the literature. Am J Dermatopathol 1999; 21: 247–52
   PubMedGoogle Scholar
• Rivest C., Miller F. W., Love L., Turgeon P. P., Blier C., Senécal J. L. Focal myositis presenting as neck pseudothrombophlebitis in mixed connective tissue disease. Arthritis Rheum 1996; 39: 1254–8
   PubMedGoogle Scholar
• Chevalier X., Larget‐Piet B., Gherardi R. Proliferative myositis as a complication of rheumatoid vasculitis. J Rheumatol 1993; 20: 1259–60
   PubMedGoogle Scholar
• Ramos‐Casals M., Brito‐Zerón P., Muñoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF‐targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242–51
   PubMed Web of Science ®Google Scholar
• Sawalha A. H., Lutz B. D., Chaudhary N. A., Kern W. K., Harley J. B., Greenfield R. A. Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol 2003; 9: 259–62
   PubMedGoogle Scholar
• Voloshin D. K., Lacomis D., McMahon D. Disseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositis. Muscle Nerve 1995; 18: 531–5
   PubMedGoogle Scholar
• Galandiuk S., Davis B. R. Infliximab‐induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 283–7
   PubMedGoogle Scholar
• Yan T. D., Kavuru M. S., Yen‐Lieberman B., Brzezinski A., Gordon S. M. Immune function evaluation (ImmuKnow Assay) in a patient treated with infliximab who developed miliary histoplasmosis. Infect Dis Clin Pract 2005; 13: 315–17
   Google Scholar
• Colombel J. F., Loftus E. V., Tremaine W. J., Egan L. J., Harmsen W. S., Schleck C. D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31
   PubMed Web of Science ®Google Scholar
• Wood K. L., Hage C. A., Knox K. S., Kleiman M. B., Sannuti A., Day R. B., et al. Histoplasmosis after treatment with anti‐tumor necrosis factor‐alpha therapy. Am J Resp Crit Care Med 2003; 167: 1279–82
   PubMed Web of Science ®Google Scholar
• Nakelchik M., Mangino J. E. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002; 112: 78–9
   PubMed Web of Science ®Google Scholar
• Zhang Z., Correa H., Begue R. E. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 623–6
   PubMedGoogle Scholar
• Giles J. T., Bathon J. M. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320–4
   PubMedGoogle Scholar
• Zaman R., Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. 40th Annual Meeting of the Infectious Diseases Society of America, 24–27 October 2002, Chicago, IL. Abstract 378
   Google Scholar
• Deepe G. S., Bullock W. E. Histoplasmosis: a granulomatous inflammatory response. Inflammation: basic principles and clinical correlates, J. I Gallin, I. M Goldstein, R Synderman. Raven Press, New York 1995; 943–58, 2nd edn
   Google Scholar
• Lee J. H., Slifman N. R., Gershon S. K., Edwards E. T., Schwieterman W. D., Siegel J. N., et al. Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565–70
   PubMed Web of Science ®Google Scholar
• Maha A. A., Mohamad S. S., Larry M. B., Glenn D. R., Randall C. W. Systemic histoplasmosis a 15‐year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007; 86: 162–9
   PubMedGoogle Scholar
• Kauffman C. A. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 2008; 21: 421–5
   PubMedGoogle Scholar
• Wallis R. S., Broder M. S., Wong J. Y., Beenhouwer D. O. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39: 1254–5
   PubMed Web of Science ®Google Scholar
• Schiff M. H., Burmester G. R., Kent J. D., Pangan A. L., Kupper H., Fitzpatrick S. B., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889–94
   PubMed Web of Science ®Google Scholar